HanchorBio Founder and Chief Executive Officer Dr. Scott Liu Receives Award from Chinese-American Biopharmaceutical Society 漢康生技創始人兼執行長 劉世高博士榮獲 北美華人生物醫藥協會2022年度方瑞賢生命科學獎

At the SAPA conference, HanchorBio presented the company’s proprietary Fc-based designer biologics (FBDB™) platform led to biological products that targeting phagocytosis checkpoint blockade and incorporating both innate and adaptive immune responses to treat patients with cancer. During the conference, HanchorBio ended with dozens of one-on-one meetings with national and international partners and multiple possible leads for in-licensing, research collaborations, or commercial right out-licensing conducted by Dr. Yi Du (Sr. Director of Business Development). These discussions mainly focused on advancing science and innovation on the development of anti-tumor immunotherapies to eliminate tumor immune escape.